High-conviction short opportunities have been identified in the quantum computing sector, specifically targeting IonQ (IONQ) and D-Wave (QBTS) due to extreme overvaluation. Another key short idea is Celestica (CLS), which is viewed as a low-margin manufacturing business trading at an unsustainable, peak-cycle valuation. For Opendoor (OPEN), a potential strategy is to initiate a short position and add to it if the stock rises towards the $15-$20 range, based on valuation concerns and a challenging housing market. On the long side, recent positions have been initiated in pharmaceutical companies Sarepta Therapeutics (SRPT) and AbbVie (ABBV). Investors should avoid Hive Digital Technologies (HIVE) due to poor profitability and a questionable business pivot.

Quantum Computing Sector

• The speaker expressed a strong bearish sentiment towards the quantum computing sector, referring to it as the "quantum short."
• He stated he has "reshorted" several companies in this space.
• Specific companies mentioned as part of this short theme include:
  • IonQ (IONQ)
  • D-Wave (QBTS)
  • Rigetti (RGTI)

Takeaways

• The speaker holds a strong conviction that quantum computing stocks are overvalued and is actively betting against them.
• IonQ (IONQ) was singled out as "one of the best shorts I've ever seen in my whole career," with the speaker believing the stock will go to zero.
• D-Wave (QBTS) was described as a "fucking trash company."
• This represents a high-risk, high-conviction thematic short position. Investors should be aware of the high volatility and potential for significant losses when shorting stocks, especially in emerging technology sectors.

Opendoor Technologies (OPEN)

• The speaker has initiated a short position in Opendoor for the first time.
• He believes the stock could continue to rise in the short term and suggests a strategy of scaling into the position: "Short a little now, short a little more at 15, short a little more at 20 if it gets there."
• He describes it as a "valuation short" and notes that he would likely cover (close out his short position) around the $13-$15 range, indicating he doesn't plan to hold the short indefinitely.
• The transcript included an Opendoor earnings call, which provided additional context:
  • Business Pivot: The company is shifting from a direct-to-consumer cash offer model to a platform model that partners with real estate agents to offer multiple products.
  • Challenging Market: Management repeatedly acknowledged a "very challenging housing market" with high mortgage rates suppressing buyer demand.
  • Financials & Guidance: While Q2 showed adjusted profitability, the company guided for a significant sequential revenue decline and an adjusted EBITDA loss for Q3. They expect a similar percentage revenue decline to continue into Q4.

Takeaways

• The speaker's short thesis appears to be based on valuation, coupled with a difficult macroeconomic environment for the housing market, as confirmed by the company's own earnings call.
• The strategy of scaling into the short position suggests an acknowledgment of the stock's potential for upward momentum, advising caution rather than taking a large position at once.
• The company's pivot to an agent-partner model is a major strategic shift. The success of this transition will be critical, but management stated its financial impact won't be seen until 2026.

Celestica (CLS)

• The speaker analyzed Celestica, an Electronic Manufacturing Services (EMS) company, and expressed a very strong bearish view.
• He called it a "juicy short" and "one of the greatest shorts ever."
• The core of his bearish argument is the company's valuation, which he views as extremely high for its business model.
  • He questioned why it trades at "40 times" free cash flow and "30 times gross profit" for what he considers a low-margin, cyclical, and "dog shit business."
  • He believes the stock is at a "peak cycle" and that its current high valuation is unsustainable.

Takeaways

• This is a strong, valuation-based short idea. The speaker believes the market is mispricing Celestica, assigning a high-tech valuation to a low-margin manufacturing business.
• Investors considering this stock should closely examine its valuation metrics (like Price-to-Free-Cash-Flow) relative to its historical performance and industry peers to determine if the current price is justified.

Hive Digital Technologies (HIVE)

• The speaker analyzed this cryptocurrency mining company upon request and was extremely bearish.
• He pointed out that even if you ignore depreciation costs for their mining equipment, the company has "extremely low margins."
• He is skeptical of the company's attempt to pivot into an AI/cloud computing business, viewing it as a common but often unsuccessful move for struggling crypto companies.
• He concluded the stock "looks like crap to me" and that he would "stay away from Hive."

Takeaways

• The speaker sees no value in the company's core crypto-mining business due to poor profitability.
• He is highly skeptical of the "pivot to AI" narrative, suggesting it may be more of a story to attract investors than a viable business strategy.
• The takeaway is to avoid this stock due to fundamental weaknesses in its business model and profitability.

ATYR Pharma (ATYR)

• The speaker had a very large, concentrated long position in ATYR, stating, "I sold everything and went all in on ATYR, guys. It's literally my only position."
• He has now sold his entire position and expressed immense relief, suggesting the investment was a high-stress, binary event (likely a clinical trial result) that resolved in his favor.
• The context implies he made a significant profit from this trade.

Takeaways

• This was a successful, high-risk, event-driven trade for the speaker.
• Now that the event has passed and he has sold his shares, there is no actionable insight for new investors other than as a case study of a high-stakes biotech investment. He is no longer involved with the stock.

Other Mentioned Stocks & Themes

Bullish Mentions

• NVIDIA (NVDA): The speaker is considering going long on NVIDIA, stating he "just need[s] something to be long." This indicates a generally positive but not deeply analyzed view.
• Sarepta Therapeutics (SRPT): He explicitly stated, "I bought some Sarepta" and confirmed he is bullish on the company.
• AbbVie (ABBV): Mentioned as a long position he "bought back" into after selling other positions.
• Palantir (PLTR): Despite some joking remarks, he stated, "Palantir is a good stock actually."

Bearish Mentions

• Hims & Hers Health (HIMS): His proprietary trading tool suggested a short on HIMS. He also called it a "tough" stock.

Stocks Identified by "PRT" Trading Tool

• The speaker showcased a proprietary quantitative tool called PRT that suggests short-term trades based on chart patterns. He placed several small trades based on its real-time recommendations. These are presented as very short-term, quantitative ideas, not long-term fundamental investments.
• Long Ideas:
  • Corteva (CTVA)
  • Wingstop (WING)
• Short Ideas:
  • Willis Towers Watson (WTW)
  • Freedom Holding Corp. (FRHC)
  • Baxter International (BAX)
  • Light & Wonder (LNW)